HK Innoen Reveals Preclinical Results of Next-Generation Lung Cancer Treatment at AACR

HK Innoen announced on the 27th that it will attend the American Association for Cancer Research (AACR) 2024, held from the 5th to the 10th of next month, to present preclinical research results of its next-generation allosteric epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) candidate through a poster presentation.

Exterior view of HK Inno.N Seoul Office
[Photo by HK Inno.N]

AACR is considered one of the world's top three cancer conferences alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Every year, numerous experts from around the world gather to share achievements in cancer research. At this conference, HK Innoen will disclose preclinical research on allosteric EGFR-TKI targeting lung cancer patients with the L858R genetic mutation.

HK Innoen is developing IN-119873, a fourth-generation targeted anticancer drug for patients who show resistance to existing first-line lung cancer treatments or have the L858R mutation. Unlike existing treatments that target the adenosine triphosphate (ATP) binding site, the energy source of cancer cells, IN-119873 targets the allosteric binding site, one of the protein sites of the EGFR mutation.

Bongtae Kim, Head of New Drug Research at HK Innoen (Executive Director), said, “We plan to present the EGFR-TKI research results to domestic and international companies and experts at AACR, while also seeking collaboration opportunities. Our goal is to complete the preclinical research of IN-119873 within this year and submit an Investigational New Drug (IND) application for Phase 1 clinical trials.”